Fast dissolving pharmaceutical compositions

An immediate release pharmaceutical composition in the form of a non-effervescent tablet, comprising:

• (a) an amorphous solid dispersion comprising dasatinib in an amount of from about 17% w/w to about 21% w/w and copovidone in an amount of from about 38% w/w to about 42% w/w;
• (b) mannitol in an amount of from about 11% w/w to 15% w/w;
• (c) at least one gas generating agent comprising sodium bicarbonate in an amount of from about 10% w/w to about 14% w/w;
• (d) crospovidone in an amount of from about 6% w/w to about 10% w/w;
• (e) at least one acidic pH modifier comprising fumaric acid in an amount of from about 2% w/w to about 6% w/w;
• (f) sodium stearyl fumarate in an amount of from about 0.1% w/w to about 4% w/w;
• and
• (g) colloidal silicon dioxide in an amount of from about 0.1% w/w to about 1% w/w;
• wherein the stated amounts are based on the total weight of the composition;
• wherein the tablet optionally comprises a coating layer;
• wherein the mole ratio of the at least one gas generating agent to the at least one acidic pH-modifier ranges from about 4:1 to about 1:4;
• and
• wherein a dasatinib dose of 100 mg provides an AUC(0-24h)fed/AUC(0-24h)fasted ratio of from about 95% to about 100%, wherein AUC(0-24h)fed corresponds to the least-squares geometric mean of the AUC(0-24h) in fed patients and wherein AUC(0-24n)fasted corresponds to the least-squares geometric mean of the AUC(0-24h) in fasted patients.